Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KRMD 
Repro Med Systems Inc (KRMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: KRMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.6
1 Year Target Price $5.6
| 4 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 26.29% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 190.03M USD | Price to earnings Ratio - | 1Y Target Price 5.6 |
Price to earnings Ratio - | 1Y Target Price 5.6 | ||
Volume (30-day avg) 5 | Beta 0.47 | 52 Weeks Range 1.86 - 5.05 | Updated Date 08/22/2025 |
52 Weeks Range 1.86 - 5.05 | Updated Date 08/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.1 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.02 | Actual 0.01 |
Profitability
Profit Margin -12.25% | Operating Margin (TTM) -3.07% |
Management Effectiveness
Return on Assets (TTM) -11.48% | Return on Equity (TTM) -25.63% |
Valuation
Trailing PE - | Forward PE 188.68 | Enterprise Value 187287166 | Price to Sales(TTM) 5.16 |
Enterprise Value 187287166 | Price to Sales(TTM) 5.16 | ||
Enterprise Value to Revenue 5.08 | Enterprise Value to EBITDA -17.15 | Shares Outstanding 46235000 | Shares Floating 33832430 |
Shares Outstanding 46235000 | Shares Floating 33832430 | ||
Percent Insiders 8.29 | Percent Institutions 55.51 |
Upturn AI SWOT
Repro Med Systems Inc
Company Overview
History and Background
Repro Med Systems Inc, doing business as KORU Medical Systems, was founded in 1980. It focuses on developing, manufacturing, and marketing innovative and easy-to-use specialty infusion solutions.
Core Business Areas
- Infusion Systems: This segment includes the Freedom System and accessories designed for subcutaneous infusion therapy. It caters to patients needing continuous infusion for various conditions.
- Consumables: This segment includes sets and disposable medical devices. These are critical for the functioning of its infusion pumps.
Leadership and Structure
The leadership team includes Linda Tharby (President & CEO), Neal Hunter (CFO), and others. The organizational structure is based on functional departments such as Sales & Marketing, Operations, and R&D.
Top Products and Market Share
Key Offerings
- Freedom System: A portable, ambulatory infusion system for subcutaneous drug delivery. Market share data is not readily available publicly. Competitors include Smiths Medical (SMIT), ICU Medical (ICUI), and Baxter International (BAX). Revenue from this product makes up most of the company's income.
- HIgH-Flo Subcutaneous Safety Needle Set: A subcutaneous needle set designed for use with the Freedom System. Market share data is not readily available publicly. Competitors include Becton Dickinson (BDX), and Medtronic (MDT).
Market Dynamics
Industry Overview
The infusion therapy market is growing due to the increasing prevalence of chronic diseases, aging populations, and advancements in drug delivery technologies.
Positioning
KORU Medical Systems focuses on the specialty infusion market, particularly subcutaneous drug delivery. Its competitive advantage lies in its portable and user-friendly infusion systems.
Total Addressable Market (TAM)
The global infusion therapy market is estimated to be in the tens of billions of dollars. KORU Medical Systems is positioned to capture a share of this market through its specialized infusion solutions. Precise TAM is difficult to ascertain without proprietary market research.
Upturn SWOT Analysis
Strengths
- Specialized in subcutaneous infusion therapy
- Portable and user-friendly infusion systems
- Strong relationships with patients and healthcare providers
- Focus on innovation and product development
Weaknesses
- Limited product portfolio
- Relatively small market share compared to larger competitors
- Dependence on single infusion system
Opportunities
- Expanding into new geographic markets
- Developing new infusion therapies and applications
- Partnerships with pharmaceutical companies
- Acquisitions to broaden product portfolio
Threats
- Competition from larger medical device companies
- Technological advancements that could render current products obsolete
- Changes in healthcare regulations and reimbursement policies
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- BAX
- ICUI
- BDX
- MDT
Competitive Landscape
KORU has advantages in its focus on portability, but it faces significant competition from larger companies with greater resources and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to assess precisely due to its recent reverse merger into Casselberry Florida Acquisition 1 Corp in 2024.
Future Projections: Future growth projections depend on the successful integration of KORU and achievement of synergies, and market conditions. Analyst estimates are not available due to lack of coverage on the stock.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts and product development initiatives.
Summary
KORU Medical Systems has a niche position in specialty infusion therapy, particularly subcutaneous delivery. Growth is driven by portability. Key is the reverse merger's integration. Competition from larger players and potential tech disruption should be watched carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Public SEC Filings
- Industry Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repro Med Systems Inc
Exchange NASDAQ | Headquaters Mahwah, NJ, United States | ||
IPO Launch date 1996-03-20 | President, CEO & Director Ms. Linda M. Tharby | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 80 | Website https://www.korumedical.com |
Full time employees 80 | Website https://www.korumedical.com | ||
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 and FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.